Drug Profile
Research programme: kidney disorder therapeutics - Goldfinch Bio
Alternative Names: DN-007; PKD-003; PKD-004; PKD-005Latest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator Goldfinch Bios
- Developer Goldfinch Bio
- Class Urologics
- Mechanism of Action TRPC5 cation channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Polycystic kidney disease
Most Recent Events
- 18 Mar 2024 Karuna Therapeutics has been acquired by Bristol-Myers Squibb
- 28 Feb 2023 No recent reports of development identified for research development in Polycystic-kidney-disease in USA
- 02 Feb 2023 Karuna Therapeutics in-licenses transient receptor potential canonical 4 and 5 (TRPC4/5) channel candidates globally from Goldfinch Bio